Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centocor's R&D spin-off Tocor

Executive Summary

On July 1, Centocor will exercise option to purchase all 2,875,000 outstanding shares of callable common stock of Tocor. Centocor spun off Tocor in 1989 to carry on research in monoclonal antibody-based therapies for inflammatory diseases ("The Pink Sheet," Jan 15, 1990, p. 14). Repurchase will be made through issuance of 2 mil. shares of Centocor stock; 1991 2nd quarter results will register a $ 71 mil. charge to earnings for acquired R&D. The deal means Centocor re-acquires rights to mAB products being developed for rheumatoid arthritis, multiple sclerosis and lupus erythematosus.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel